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PREFACE
My interest in the use of antibiotics in general was sparked during the three years that I 
worked in the Republic of Ireland, where antibiotic resistance is becoming a significant 
medical conundrum. I began reading information behind antibiotic protocols and soon 
realized that the evidence base for many of our so called routines is quite poor. On return to 
South Africa, during a ward round where we were discussing a patient for endoscopic 
retrograde cholangiopancreaticogram, the question was raised, does he need prophylactic 
antibiotics? Recently qualified consultants often related stories of how it was their 
responsibility that each and every patient going down to the scope room had to have their 
drip up, connected to that essential vaculitre containing an antibiotic. If not, they were liable 
to be hung, drawn and quartered at the next available opportunity by their consultant. No one 
questioned why, it was assumed to be the right thing to do. This led me to ask the question 
why?
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ABSTRACT
Background
The use of prophylactic antibiotics before endoscopic retrograde cholangiopancreatography 
(ERCP) is recommended by all major international gastroenterological societies, especially in 
the presence of an obstructed biliary system. Their use is intended to decrease or eliminate 
the incidence of complications following the procedure, namely cholangitis, cholecystitis, 
septicaemia, and pancreatitis.
Objectives
To assess the benefits and harms of antibiotics before elective ERCP in patients without 
evidence of acute or chronic cholecystitis, or acute or chronic cholangitis, or severe acute 
pancreatitis.
Data collection and analysis
We audited South African endoscopists who perform ERCPs in the form of a questionnaire. 
The review was conducted according to the recommendations of The Cochrane Collaboration 
as well as the Cochrane Hepato-Biliary Group. Review Manager 5 was used employing 
fixed-effect and random-effects model meta-analyses. Only randomised clinical trials were 
included in the analyses, irrespective of blinding, language, or publication status. Participants 
were patients that underwent elective ERCP that were not on antibiotics, without evidence of 
acute or chronic cholecystitis, cholangitis, or severe acute pancreatitis before the procedure. 
We compared patients that received prophylactic antibiotics before the procedure with 
patients that were given placebo or no intervention before the procedure.
Results
The audit revealed that no specific protocols were being implemented in South Africa, and 
there was a marked difference in the practice between surgical and medical 
gastroenterologists, with surgeons using antibiotics more often. There was also a wide 
spectrum of antibiotic types and combinations being used.
Nine randomised clinical trials (1573 patients) were included into the review analyses. The 
majority of the trials had risks of bias. When all patients providing data for a certain outcome 
were included, the fixed-effect meta-analyses significantly favoured the use of prophylactic 
antibiotics in preventing cholangitis (relative risk (RR) 0.54, 95% CI 0.33 to 0.91), 
septicaemia (RR 0.35, 95% CI 0.11 to 1.11), bacteriaemia (RR 0.50, 95% CI 0.33 to 0.78), 
and pancreatitis (RR 0.54, 95% CI 0.29 to 1.00). In random-effects meta- analyses, only the 
effect on bacteriaemia remained significant. Overall mortality was not reduced (RR 1.33, 
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95% CI 0.32 to 5.44). If one selects patients in whom the ERCP resolved the biliary 
obstruction at the first procedure, there seem to be no significant benefit in using prophylactic 
antibiotics to prevent cholangitis (RR 0.98, 95% CI 0.35 to 2.69, only three trials).
Conclusions
Prophylactic antibiotics reduce bacteriaemia and seem to prevent cholangitis and septicaemia 
in patients undergoing elective ERCP. In the subgroup of patients with uncomplicated ERCP, 
the effect of antibiotics may be less evident. Further research is required to determine 
whether antibiotics can be given during or after an ERCP if it becomes apparent that biliary 
obstruction cannot be relieved during that procedure.
Page | 12 
CHAPTER 1
1. INTRODUCTION
1.1 Literature review
Endoscopic retrograde cholangiopancreatography (ERCP) involves cannulation of the 
ampulla of Vater. It is a modality that combines endoscopic and fluoroscopic techniques. 
Through the endoscope, the physician can see the inside of the stomach and duodenum, and 
can inject dye into the ducts in the biliary tree and pancreas via the ampulla of Vater. Using 
fluoroscopy the ductal anatomy can be seen on x-rays.
 Thus it has diagnostic as well as therapeutic capabilities, although the number of non-
therapeutic ERCP’s is decreasing 1. Diagnostically it is used in the investigation of jaundice, 
assessment of the bile ducts before or after cholecystectomy, in the investigation of 
abdominal pain thought to be of pancreatic origin, and in diagnosing sphincter of Oddi 
dysfunction. Therapeutic benefits include evacuation of ductal gallstones and the palliation of 
biliary and pancreatic strictures 2. Endoscopic sphincterotomy, stone extraction, and stenting 
are not without complications. The most widely recognized of these include bleeding 
(0.7-2%), perforation (0.3-0.6%), pancreatitis (7%), cholangitis (1%) and cholecystitis 
(0.2-0.5%) of patients. Procedure-related mortality is between 0.3% to 1% of patients 3,4. In 
addition ERCP induces a transient bacterobilia and bacteraemia 5.
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A  review of international guidelines regarding the use of prophylactic antibiotics with ERCP 
show that the routine use of antimicrobials is recommended for biliary obstruction and 
pancreatic pseudocysts. Whether antibiotics, such as ciprofloxacin, clindamycine, 
gentamicin, cefuroxime, and others reduce the incidence of cholangitis could not be proven in 
several studies 5-7. It has also been postulated that antibiotics will reduce the incidence of 
pancreatitis following ERCP 8.
A recent review of the literature highlighted a meta-analysis of seven trials, concluding that 
there was no benefit in prescribing prophylactic antibiotics before commencing ERCP9.
1.2 Hypothesis
There is no difference in the incidence of infective complications following ERCP in patients 
receiving prophylactic antibiotics compared to those not receiving antibiotics.
1.3 Objectives
To determine South African ERCP endoscopist prophylactic antibiotic practice, followed by 
an  assessment of the level of evidence in the literature through a meta-analysis.
1.4 Aims
To determine whether or not we should be using routine prophylactic antibiotics with every 
ERCP, or on an individual patient case scenario, or at all. 
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CHAPTER 2
2. METHODS OF INVESTIGATION
2.1 Assessment of South African practice 
Before commencing the study, and in order to ascertain what the current antibiotic practice is 
amongst South African endoscopists who perform ERCP’s, an anonymous questionnaire was 
handed out during the annual Hepato-Biliary Association of South Africa meeting in 2008. It 
was also sent via email to all members of the South African Gastro-Enterology Society. A 
copy of the questionnaire appears in appendix 1.
2.2 Meta-analysis
The meta-analysis was carried out according to the principles of a Cochrane review, using the 
suggested statistical software (Revman software). The latter requires that two investigators 
review the literature. Dr Peter O Farrel and I performed the literature review, and acquisition 
of copies of all applicable studies.
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2.2.1 Outcome measures
Primary outcome measures
· All-cause mortality.
· Acute cholangitis (right upper quadrant pain, pyrexia, and elevated inflammatory 
markers).
· Septicaemia (positive blood cultures with a systemic inflammatory response).
· Adverse drug events: The International Conference on Harmonisation Guidelines 35 
defines adverse events as serious and non-serious. A serious fatal or nonfatal adverse 
event is any event that leads to death, is life-threatening, requires in-patient 
hospitalisation or prolongation of existing hospitalisation, results in persistent or 
significant disability, and any important medical event, which may have jeopardised 
the patient or requires intervention to prevent it. All other adverse events will be 
considered non-serious. This outcome is specific for antibiotic or placebo-related 
events.
· Quality of life.
Secondary outcome measures
· Mortality directly attributable to ERCP-induced sepsis.
· Bacteraemia (positive blood cultures with no evidence of a systemic inflammatory 
response).
· Pancreatitis (a three-fold rise of serum amylase accompanied with abdominal pain).
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2.2.2 Format of literature search
Electronic searches
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register10, the Cochrane 
Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 4, 2009), 
MEDLINE (1974 to October 2009), EMBASE (1980 to October 2009), LILACS (1982 to 
October 2009), and Science Citation Index Expanded (1974 to October 2009)11 .The search 
strategies with the time span of the searches are given in Appendix 2.
Conference proceedings
· The Society of American Gastrointestinal and Endoscopic Surgeons annual meeting 
(2000 to 2008).
· American Society for Gastrointestinal Endoscopy annual meeting (1974 to 2008).
· United European Gastroenterology Week (1992 to 2008).
· British Society of Gastroenterology annual scientific meeting (1980 to 2008).
· Canadian Digestive Diseases Week (1974 to 2008).
Reference list
Reference lists of all studies identified by the above methods were also searched.
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2.2.3 Criteria for considering studies for this review  
Types of studies  
We included randomised clinical trials only, irrespective of blinding, language, or publication 
status. Quasi-randomised clinical trials, cross-over trials, cohort studies, and case control 
studies were excluded.
Types of participants  
Our meta-analysis included patients that underwent elective ERCP that were not on 
antibiotics, without evidence of acute or chronic cholecystitis, cholangitis, or severe acute 
pancreatitis before the procedure.
Types of interventions  
Patients given prophylactic antibiotics before the procedure were compared to patients that 
were given a placebo or no intervention before the procedure. Trials were included regardless 
of the type, dose, or route of administration of the antibiotic.
2.2.4 Selection of studies and data extraction
Martin Brand (MAB) and Peter O'Farrell (PEF) independently identified trials for inclusion 
using the criteria specified above, as well as searched the references of these studies for 
further relevant trials. None of the studies matching the above mentioned criteria were 
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excluded. No language or publication status restrictions were applied. MAB and PEF 
independently extracted the following data from identified trials:
· Year and language of publication
· Year of study
· Inclusion and exclusion criteria
· Sample size
· Indication of intervention
· Type, dose, and route of prophylactic antibiotic
· Incidence of complications
· Methodological quality.
MAB and PEF recorded whether the authors of the trials used a sample size calculation, and 
whether or not they made their analyses using an intention-to-treat principle. The bias risk of 
each trial was independently assessed. Any unclear or missing information was clarified by 
contacting the authors of the specific trial. Differences in opinion between the authors 
extracting data were resolved through discussion. 
2.2.5 Assessment of the risk of bias of included trials
Generation of the allocation to treatment group sequence
The sequence generation of trial allocation was described as either Yes adequate/ Unclear/ No 
inadequate as follows:
- Yes adequate: sequence generation was achieved using computer random number 
generation or a random number table. Drawing lots, tossing a coin, shuffling cards and 
throwing dice are adequate if performed by an independent adjudicator.
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- Unclear: the trial is described as randomised but the method of sequence generation was not  
specified.
- No inadequate: the sequence generation method is not, or may not be, random. Quasi-
randomised studies, those using dates, names, or admittance numbers in order to allocate 
patients are inadequate and will be excluded for the assessment of benefits but not for harms.
Allocation concealment
- Yes adequate: allocation was controlled by a central and independent randomisation unit, 
opaque and sealed envelopes or similar, so that intervention allocations could not have been 
foreseen in advance of, or during, enrolment.
- Unclear: the trial was described as randomised but the method used to conceal the allocation 
was not described, so that intervention allocations may have been foreseen in advance of, or 
during, enrolment.
- No inadequate: if the allocation sequence was known to the investigators who assigned 
participants or if the study was quasi-randomised. Quasi-randomised studies will be excluded 
for the assessment of benefits but not for harms.
Blinding
- Yes adequate: the trial was described as double blind and the method of blinding was 
described, so that knowledge of allocation was adequately prevented during the trial.
- Unclear: the trial was described as double blind, but the method of blinding was not 
described, so that knowledge of allocation was possible during the trial.
- No not performed: the trial was not double blind, so that the allocation was known during 
the trail.
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Incomplete outcome data
- Yes adequate: the numbers and reasons for dropouts and withdrawals in all intervention 
groups were described or if it was specified that there were no dropouts or withdrawals.
- Unclear: the report gave the impression that there had been no dropouts or withdrawals, but 
this was not specifically stated.
- No inadequate: the number or reasons for dropouts and withdrawals were not described.
Selective outcome reporting
- Yes adequate: pre-defined, or clinically relevant and reasonably expected outcomes are 
reported on.
- Unclear: not all pre-defined, or clinically relevant and reasonably expected outcomes are 
reported on or are not reported fully, or it is unclear whether data on these outcomes were 
recorded or not.
- No inadequate: one or more clinically relevant and reasonably expected outcomes were not 
reported on; data on these outcomes were likely to have been recorded.
Any other bias
- Yes adequate: the trial appears to be free of other components that could put it at risk of 
bias.
- Unclear: the trial may or may not be free of other components that could put it at risk of 
bias.
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- No inadequate: there are other factors in the trial that could put it at risk of bias, eg, no 
sample size calculation made, early stopping, industry involvement, or an extreme baseline 
imbalance.
Trials with an adequate generation of allocation sequence, allocation concealment,  blinding 
and handling of incomplete outcome data, with no selective outcome reporting, or other bias 
risks were considered low-bias risk trials. Trials with one or more unclear or inadequate 
quality components were considered high-bias risk trials. However, in such a large number of 
reviews optimal division of trials may not be possible.
2.2.6 Measurement of treatment effect
Dichotomous data were analysed for relative risk ratio (RR) and the absolute effects were 
measured with the risk differences. Calculation of 95% confidence intervals were done for 
these measures of effect. Treatment effect was also considered by using available case 
analysis.
The Mantel-Haenszel method was used for the meta-analysis 12,13. Results are presented on a 
forest plot graphic.
2.2.7 Heterogeneity and subgroup analysis
Statistical heterogeneity was tested using the I2 test 14and chi-squared test, with a P-value of 
0.10 representing statistical significance. If heterogeneity was identified, we considered 
performing subgroup analyses. Subgroups that were considered included diagnostic 
compared with therapeutic ERCP's, biliary compared with pancreatic indications for ERCP, 
different antibiotics, and trials with low bias risk compared to trials with high bias risk (one 
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or more than one of the components inadequate or unclear). When the results in the fixed-
effect and random-effects models did not differ, we reported the fixed-effect model.
2.2.8 Sensitivity analysis
MAB and PEF independently performed sensitivity analyses at the end of the review by 
examining the trial inclusion criteria, reassessing excluded trials, re-analysing data imputed, 
and re-analysing data using the Der Simonian and Laird method 15.
2.2.9 Funnel plot
We used a funnel plot to explore bias 16,17. A linear regression approach described by Egger et 
al 16 was used to determine the funnel plot asymmetry. 
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CHAPTER 3
3. RESULTS
3.1 Standard practice of South African endoscopists
Thirty nine endoscopists (22 surgeons, 16 physicians and 1 radiologist) responded to our 
questionnaire. The majority of these endoscopists had more than six  years of experience 
(30/39) and performed more than 10 ERCP’s per month (22/39). Approximately half (19/39) 
were aware of ERCP antibiotic protocols, either the ASGE or NHS recommendations. 
Comparisons between surgeons verse other endoscopists in using antibiotics during the 
various procedures were conducted and the results are shown in table 1 below. ‘Always’ 
implied that the endoscopist used antibiotic prophylaxis with each patient, ‘selected’ with 
specific indications and ‘never’ implied no usage of antibiotic prophylaxis.
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                      SURGEONS
                       (n=22)
PHYSICIANS & RADIOLOGIST
                     (n=16+1)
p-values
ERCP Always Selected Never Always Selected Never
Diagnostic 
biliary
Diagnositic 
pancreatic
Therapeuti
c biliary
Therapeuti
c 
pancreatic
14
13
19
19
5
6
2
2
3
3
1
1
2
2
5
5
8
4
10
9
5
11
2
3
0.01
0.0018
0.012
0.0014
Table1: Audit results
It is clear from the audit results that surgeons are more likely to use antibiotics for any 
indication of ERCP, compared to other endoscopists.  There were no endoscopists that 
performed sphincter of Oddi pressure studies. The preferred prophylaxis was piperacillin-
tazobactam (14/39), followed by gentamicin (8/39), cephalosporins (6/39), ciprofloxacin 
(4/39) and co-amoxiclavulanic acid (3/39). Thirty endoscopists administered their antibiotic 
as a single dose before the procedure, 5 preferred a 24 hour course, 3 for 48 hours and 1 gave 
antibiotics for 5 days. All except three administered the antibiotics intravenously.
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3.2 Meta-analysis 
3.2.1. Description of Included Studies
Our search strategy identified forty-nine references, nine of which were potentially eligible 
trials, and all of these trials have been included in this review. Of the forty studies that were 
not included in our review, thirty three were not placebo controlled trials and compared 
antibiotic regimes with one another. Five were not randomised control trials and two included 
patient's that were already on antibiotic treatment for their disease. All the exclusions were 
based on the title or abstract.
Brandes et al 18 performed their trial in Braunschweig, Germany. One-hundred and eighteen 
patients were randomised into three groups. One group received no prophylaxis (n = 39), the 
second received 200 mg oral minocycline (n = 39), the third group received no antibiotics but 
were kept fasting and had a nasogastric tube placed for 36 hours after the ERCP (n = 40). For 
the purposes of this review, the two groups that did not receive any antibiotics were 
combined and assessed as one group.
Byl et al 19 performed their trial in the Erasme Hospital, Brussels, Belgium. Initially 82 
patients were randomised, of which 14 were excluded. Grounds for exclusion included two 
with positive blood cultures before ERCP, three failed cannulations, two were discovered to 
have cholangitis during the ERCP, two had previous antimicrobial therapy, and five had 
incorrect drug administration. After the procedure, the patients were divided into two groups. 
Those that had complete biliary drainage had their treatment discontinued, while those who 
did not have complete drainage had their antibiotic or placebo administered until the 
obstruction was relieved by successive ERCP procedures for a maximum of seven days.
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Llach et al 5 carried out their trial in Barcelona, Spain. The aim of the trial was to analyse the 
efficacy of intramuscular clindamycin and gentamicin before ERCP. It was not clear from the 
publication whether or not the patients that developed cholangitis had undergone a diagnostic 
or therapeutic ERCP. It was also not clear if biliary obstruction was diagnosed at ERCP, if it 
was completely relieved.
Lorenz et al 6 performed their trial in Munich, Germany. Patients were included if they had 
either a biliary or pancreatic obstruction, and were to undergo either an ERCP or 
percutaneous transhepatic cholangiography (PTC) with drainage. Initially 110 patients were 
randomised; however, 11 were excluded. Of these, only six had a diagnostic procedure, three 
failed CBD cannulations, one patient was already on antibiotics, and another patient had 
clinical evidence of cholangitis before the procedure. There were 86 patients that underwent 
ERCP alone, 40 in the prophylaxis group, and 46 in the control group. These were the 
patients that we considered for our review. We excluded the PTC patients.
Niederau et al 20 included patients who were likely to undergo a therapeutic or complicated 
diagnostic ERCP. The trial took place in Dusseldorf, Germany. Initially 124 patients were 
recruited, but following randomisation, 24 were excluded. These included 16 patients that 
only had diagnostic ERCP's, and eight failed procedures. During the follow-up period 
antibiotics were only given if there was clinical and bacteriological evidence of septic 
cholangitis. No antibiotic prophylaxis was given to the 33 patients in the control group in 
whom the biliary obstruction could not be relieved.  It was not stated if the complications that 
occurred in the control group were amongst those patients in whom the biliary obstruction 
was or was not relieved.
Räty et al 21 aimed at evaluating whether or not antibiotic prophylaxis had any effect on post 
ERCP pancreatitis versus post ERCP cholangitis. The trial was performed in Tampere, 
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Finland. A total of 321 patients were randomised; however, six were excluded due to failure 
in relieving the biliary obstruction, leaving 155 patients in the prophylaxis group and 160 in 
the control group.
Sauter et al 7 performed their trial in Munich, Germany. A total of 96 patients were recruited, 
with 100 ERCP's being performed; fifty in the prophylaxis as well as the control groups. It 
was not stipulated why four patients had to undergo a second ERCP, and if they were in the 
control or study groups.
Spicak et al 22 undertook a multicentre trial performed in the Czech Republic. Patients were 
randomised before the ERCP to receive either antibiotic or no treatment, and included into 
the trial analysis if the obstruction was relieved at the first ERCP.
Van den Hazel et al 8 performed their trial in Amsterdam, Holland. They randomised 562 
patients, but 11 were excluded as they met major exclusion criteria. No antibiotic was to be 
administered as prophylaxis after the procedure. Patients that had been referred to their centre 
were transferred back to their local hospital for observation and further management after the 
ERCP. Patients were discharged on the day of the procedure if no abnormality had been 
found, and no interventions had taken place. After the ERCP the physicians responsible for 
the patient were asked to record the patient’s body temperature until their discharge or for the 
first 48 hours after the ERCP. Follow-up information was obtained through a telephone 
interview with the attending physician for the first 2 days after the ERCP. After seven days 
the patient was contacted telephonically in a structured interview. It was not mentioned how 
many patients eventually underwent only a diagnostic ERCP without any interventions. 
Forty-four patients were inadvertently given antibiotics at their local hospitals (16 in the 
prophylaxis group, and 28 in the placebo group), while 53 patients underwent a second 
ERCP. All these patients were included in the final analyses, and it is not mentioned how 
Page | 28 
many of these patients had complications. Nineteen patients had a significant complication 
during their initial ERCP and were still included in the final statistics. These complications 
included: seven haemorrhages, six perforations of the common bile ducts, four gastro-
intestinal tract perforations, one stent release mechanism failure, and one bradycardia. 
Table 2 and Table 3 tabulate the characteristics of included studies.
Study Cholangitis Hyperamylasaemi
a
Pancreatitis
Brandes 
18
Clinical signs not specified Not applicable Clinical signs not 
specified
Byl 19 Right upper quadrant pain and 
fever (axillary temp.  >38.5 °C)
Not applicable Not applicable
Llach 5 Fever (temp. >38°C), increasing 
jaundice or rising bilirubin level 
and a positive blood culture
Not applicable Not applicable
Lorenz 6 Positive blood culture and two of 
four criteria: fever, rigor, systemic 
response  (tachycardia), 
leokocytosis or leukopenia
Not applicable Not applicable
Niederau 
20
Clinical signs not specified Not applicable Not mentioned
Räty 21 Rising fever over 2 days, increased
CRP, leukocyte count and liver 
function values
Serum amylase > 
900IU/L
Clinical findings,  
serum amylase
>900IU/L, 
increased CRP level 
and
leukocyte count 
with no signs of 
cholangitis
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Sauter7 Clinical signs, fever >38°C and 
leukocytosis of >10000/mm3.
Serum amylase
>120 IU/L or
doubling of pre-
ERCP level
Not specified
Spicak 22 Pyrexia > 38.5°C, with
the exclusion of other causes of 
infection
Protracted pain
with a three fold
rise in serum 
amylase
Not applicable
Van den 
Hazel 8
Temperature >38°C, if
clinical symptoms (right upper
quadrant pain or jaundice) were
severe enough to commence
antibiotics, and no cause of fever
outside of the biliary tract was 
identified
Not applicable Not applicable
Table 2: Study definitions of cholangitis, hyperamylasaemia, and acute pancreatitis
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Study Male Female Age
Controls AB group Controls AB Controls AB
Brandes 18 No information supplied
Byl 19 21 20 13 14 66.5± 16.3 67.1± 11.6
Llach 5 28 33 69± 7.6
Lorenz 6 51 48 60.6± 19.2 61± 17
Niederau20No information supplied
Räty 21 71 61 89 94 63 (60-65) 59 (57-62)
Sauter 7 43% 53% 57% 47% 57.2± 16 59.3± 14
Spicak 22 No information supplied
Van den 
Hazel 8
125 122 156 148 66.2± 15.1 67.5± 14.3
Table 3: Study demographics
3.2.2 Risk of Bias of Included Studies
All included trials were randomised controlled trials. Five had adequate generation of 
allocation sequence 7,8,19,21,22,  and four trials had adequate allocation concealment 7,8,19,21.
Only two trials 8,19 were double blind, having both the attending physicians and patients were 
blinded, and thus the two trials had adequate blinding.
Incomplete outcome data and selective outcomes were reported in all trials but two, where 
there was not enough information in the text 8,18. Consequently, it was also not possible to 
report whether or not there were other sources of bias in these two trials. The remaining 
seven trials had a low risk of bias in regard to their incomplete outcome data, and all seven 
trials were free of selective outcome reporting. After considering the risk of bias of all nine 
trials, we concluded that only Byl et al 19was a low risk of bias trial. Although Van den Hazel 
et al 8 had adequate generation of allocation sequence and allocation concealment with 
blinding, the trial is at high risk of bias due to transgressions in its antibiotic protocol. The 
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remaining trials also high bias risk due to the fact that they were unblinded. The risk of bias 
in all trials is illustrated in figure 1 and figure 2.
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Figure 1: Methodological quality graph: each methodological quality item is presented as a 
percentage across all included studies.
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   Figure 2: Methodological quality summary
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3.2.3__Effects of Interventions
Primary outcome measures
All cause mortality
Nine randomised clinical trials that compared antibiotic prophylaxis to no antibiotic 
prophylaxis before ERCP were included in the analyses. Total mortality was 7 out of 1294 
patients, with four in the antibiotic group, and three in the control group. This gives a relative 
risk ratio (RR) of 1.29 CI (0.35 to 4.74) P = 0.71, I2 0% (Figure 3). 
Figure 3
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Acute cholangitis (right upper quadrant pain, pyrexia, and elevated inflammatory 
markers)
Eight trials were included to assess the incidence of cholangitis. This occurred in 61 out of 
1474 patients; 21 out of 706 received antibiotics and 40 out of 768 received no antibiotics, 
with a relative risk ratio of 0.57 CI (0.34 to 0.94) P = 0.02, I2 0% (Figure 4). When we 
considered the sub group of patients that underwent a successful first ERCP to relieve a 
biliary obstruction, we were only able to include information from three studies. There were 
20 cases of cholangitis out of 624 patients; 6 out of 302 in the prophylaxis group and 14 out 
of 322 patients in the control group. This gave a relative risk ratio of 0.98 CI (0.35 to 2.69) P 
= 0.96, I2 0% (Figure 5).
Figure 4
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Figure 5
Septicaemia (positive blood cultures with a systemic inflammatory response)
We analysed six trials for the incidence of septicaemia and bacteraemia following ERCP. 
Septicaemia occurred in 27 of 973 patients, 5 out of 480 in the antibiotic group and 21 out of 
493 in the control group. RR is 0.35 CI (0.11 to 1.11) P = 0.07, I2 24% (Figure 6).
Figure 6
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Adverse events 
Only one trial documented adverse drug events. The trial by Van Den Hazel 8 reported one 
non-serious adverse event in the placebo group.
Quality of life 
None of the trials used quality of life as an outcome measure.
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Secondary  outcome measures
Mortality directly attributable to ERCP-induced sepsis
We were unable to determine the number of deaths directly attributable to ERCP-induced 
sepsis as this was not mentioned in most studies.
Bacteraemia (positive blood cultures with no evidence of a systemic inflammatory 
response)
Bacteraemia occurred in 77 of 579 patients, 24 out of 283 in the antibiotic group, and 53 out 
of 296 in the control group. This gave a RR of 0.50 CI (0.33 to 0.78) P = 0.002, I2 47% 
(Figure 7).
Figure 7
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Pancreatitis (a three-fold rise of serum amylase accompanied with abdominal pain)
Only four trials considered pancreatitis as an outcome. The overall incidence was 43 patients 
out of 698; 14 out of 321 in the antibiotic group and 29 out of 377 in the control group. RR is 
0.54 CI (0.29 to1.0) P = 0.05, I2 10% (Figure 8).
Figure 8
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CHAPTER 4
4. DISCUSSION
4.1 South African endoscopy practice
Currently there are 101 gastroenterologists registered with the Health Professions Council of 
South Africa, consisting of 26 surgeons and 76 physicians, many of whom do not perform 
ERCP’s. The 39 doctors who responded to our questionnaire probably represent the majority
( at least 80%)of those practitioners who regularly perform ERCP’s. The results of our 
questionnaire demonstrate that there is no consistent antibiotic protocol followed by South 
African endoscopists, and that that there is also a significant difference in antibiotic usage 
between surgeons and non-surgeons. It is postulated that surgeons used antibiotics more often 
as they are more likely to deal with cases of severe pancreatic sepsis and this may influence 
their prescribing habit. There appears to be no adherence to evidence based medicine or 
guidelines in South Africa in this regard.
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4.2 Meta-analysis
We observed a significant difference in the incidence of bacteriaemia, cholangitis, 
septicaemia, and pancreatitis favouring the antibiotic prophylaxis group in fixed-effect 
model meta-analyses. In random-effects model meta-analyses, we were only able to 
confirm these effects regarding bacteraemia. We were unable to show a statistically 
significant difference in all-cause mortality after the administration of prophylactic 
antibiotics to all patients undergoing an ERCP, neither with a fixed-effect nor a random-
effects model meta-analysis. We were unable to conduct meta-analyses of adverse events 
and quality of life.
The patient number needed to treat (NNT) to prevent one episode of cholangitis seems to 
be 38 patients. Bacteraemia occurred significantly less in the antibiotic groups, as did 
ensuing septicaemia; however, there was a significant heterogeneity in these two 
outcomes, possibly attributed to incomplete ERCP procedures. Unfortunately, we were not 
able to elucidate this from most trials, as not enough details were supplied in the text. The 
NNT to prevent one episode of septicaemia seems to be 31 patients, and NNT to prevent 
one episode of bacteraemia seems to be 11 patients. The incidence of pancreatitis was 
lower in the antibiotic prophylaxis group, with minimal heterogeneity amongst the included 
trials.
There are a number of weaknesses with the present evidence on which this systematic 
review rests. First, the majority of the included trials had high risk of bias. This raises the risk 
of observing beneficial intervention effects that may not be real 26-29. Second, the number of 
patients randomised and the number of patients with outcomes were small for all outcome 
measures. This increases the risk of random errors due to sparse data as well as multiplicity 
from repeated testing on accumulating evidence 30-34. Third, a variable number of antibiotics 
have been used so it is not possible to determine which may and may not provide 
prophylactic effects. Fourth, we could not assess adverse events like allergy, development of 
antibiotic resistance, quality of life, etc. This was due to insufficient reporting in the primary 
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trials. Fifth, the assessment of the effect of antibiotics on most of our outcome measures 
seems to be influenced by choice of statistical method. This questions the robustness of our 
present evidence.
Our sub-group analysis showed that the likely benefit observed in all patients could not be 
demonstrated in the subgroup of patients with a successful first ERCP procedure relieving 
the biliary obstruction. This can be due to lack of statistical power in this subgroup or due to 
lack of effect. Based on the latter possibility, we question whether or not antibiotics should 
be routinely administered before the ERCP procedure. One could argue that up to a few 
hours delay of antibiotic administration would not harm the patient, as it has been well 
documented that patients with obstructive jaundice achieve an antibiotic concentration in 
bile that is below the minimum inhibitory concentration of bacteria 23-25. Hepatic 
dysfunction only improves once the cause of jaundice is reversed, ie, obstruction relieved 23.
Our results differ from a recent meta-analysis 9 assessing the incidence of 
cholangitis and septicaemia in unselected ERCP patients. In this meta-analysis the patients 
did not seem to benefit from antibiotic prophylaxis. The meta-analysis only conducted 
random-effects model meta-analyses in case of heterogeneity.
The incidence of pancreatitis was lower in the antibiotic prophylaxis group, with minimal 
heterogeneity amongst the included trials. NNT is 44.
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CHAPTER 5
5. CONCLUSIONS
5.1 Implications for practice
· Routine antibiotic prophylaxis before elective ERCP seems to reduce bacteraemia 
and may reduce cholangitis, septicaemia, and pancreatitis. We could not 
demonstrate a significant effect on all-cause mortality. We lack data on the effect of 
antibiotics on adverse effects and quality of life.
· The potential effect of antibiotics on cholangitis seems largest in patients with a 
         difficult ERCP procedure.
5.2 Implications for research 
! We need more randomised clinical trials comparing antibiotics versus placebo for 
patients undergoing therapeutic biliary ERCP. These trials need to be with low risk of 
bias (systematic errors) and low risk of play of chance (random errors).
· We need randomised clinical trials on patients undergoing therapeutic biliary ERCP 
assessing antibiotic usage before the procedure versus antibiotic administration 
during or after the procedure. A clinical score should be developed to predict the 
probability of ERCP procedural failure.
· We need a systematic review of the randomised trials that have compared 
antibiotics head-to-head in patients undergoing therapeutic biliary ERCP.
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APPENDIX 1
ERCP and prophylactic antibiotics: a questionnaire
Thank you for taking the time to fill in our voluntary, anonymous questionnaire regarding 
endoscopic retrograde cholangiopancreatography and the use of prophylactic antibiotics.
Demographics:
What is your speciality?
Surgeon  !  Medical gastroenterologist  !  Radiologist  !
Where do you practice?
Public sector !  Private sector !  Both !
How many ERCP’s do you perform in a month?
0-4 !  5-9 !  more than 10 !
For how many years have you performed ERCP’s?
Less than 1year  !      1 to 5years !     5-10years     !      More than 10years   !
Do you perform out of hours ERCP?
No  ! Yes  ! 
Prophylactic antibiotics:
(If a patient is not already on antibiotics eg for cholangitis, pancreatitis)
Do you use prophylactic antibiotics for the following:
For purely diagnostic biliary ERCP?    Always  ! Selected cases !        Never !
For purely diagnostic pancreatic ERCP?  Always !  Selected cases !        Never !
For therapeutic biliary ERCP? Always  ! Selected cases !        Never !
For therapeutic pancreatic ERCP? Always  ! Selected cases !        Never !
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If so, which antibiotic is your antibiotic of choice? (please mark only one)
Augmentin  !    Ciprobay  !     Tazocin  !   Any Cephalosporin  !     Gentamicin   !
Other___________________
For how long do you give prophylactic antibiotics?
Single dose  !   24hours  ! 48hours  ! Longer, how long  ________________
Which route of administration do you prefer?
Intravenous  !    Oral  !
Are you aware of any antibiotic protocols for ERCP?
No  ! Yes  !
If so, which ones?
British  !  American  !   Other, please name___________________
Do you perform manometry for assessment of the Sphincter of Oddi
No  ! Yes !
If you do perform manometry, do you use prophylactic antibiotics?
No  ! Yes  !
Thank you again for your time.
Please drop your completed questionnaire into the marked box at the exit, and enter 
your name into the register so that we don’t contact you after the congress in this regard 
again.
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APPENDIX 2
DATABASE PERIOD OF 
SEARCH
SEARCH STRATEGY
The Cochrane Hepato-Biliary 
Group Controlled Trials 
Register
October 2009 (antibiotic AND prophylaxis) AND 
('endoscopic
retrograde cholangiopancreatography')
Cochrane Central Register of 
Controlled Trials (CENTRAL) 
in the Cochrane Library
Issue 4, 2009 #1 MeSH descriptor Antibiotic 
Prophylaxis explode all trees
#2 MeSH descriptor 
Cholangiopancreatography,
Endoscopic Retrograde explode all 
trees
#3 (#1 AND #2)
Medline 1950-October 
2009
#1 explode "Antibiotic-Prophylaxis"/ 
all subheadings
#2 explode 
"Cholangiopancreatography-
Endoscopic-Retrograde"/ all 
subheadings
#3 #1 and #2
#4 random* or control* or blind* or 
meta-analys*s
#5 #3 and #4
Embase 1980-October 
2009
#1 explode "antibiotic-prophylaxis"/ 
all subheadings
#2 explode "endoscopic-retrograde-
cholangiopancreatography"/ all 
subheadings
#3 #1 and #2
#4 random* or blind* or meta-
analys*s or control*
#5 #3 and #4
Science Citation Index 
Expanded
(http://
pcs.isiknowledge.com)
1945-October 
2009
#1 TS=antibiotic prophylaxis
#2 TS=endoscopic retrograde
cholangiopancreatography
#3 #1 AND #2
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